| Literature DB >> 25147793 |
Priyam Sinha1, Shruti Srivastava1, Nidhi Mishra1, Narayan Prasad Yadav1.
Abstract
Acne is a common but serious skin disease, which affects approximately 80% adolescents and young adults in 11-30 age group. 42.5% of men and 50.9% of women continue to suffer from this disease into their twenties. Bacterial resistance is now at the alarming stage due to the irrational use of antibiotics. Hence, search for new lead molecule/bioactive and rational delivery of the existing drug (for better therapeutic effect) to the site of action is the need of the hour. Plants and plant-derived products have been an integral part of health care system since time immemorial. Therefore, plants that are currently used for the treatment of acne and those with a high potential are summarized in the present review. Most active plant extracts, namely, P. granatum, M. alba, A. anomala, and M. aquifolium exhibit minimum inhibitory concentration (MIC) in the range of 4-50 µg/mL against P. acnes, while aromatic oils of C. obovoides, C. natsudaidai, C. japonica, and C. nardus possess MICs 0.005-0.6 μL/mL and phytomolecules such as rhodomyrtone, pulsaquinone, hydropulsaquinone, honokiol, magnolol, xanthohumol lupulones, chebulagic acid and rhinacanthin-C show MIC in the range of 0.5-12.5 μg/mL. Novel drug delivery strategies of important plant leads in the treatment of acne have also been discussed.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25147793 PMCID: PMC4132408 DOI: 10.1155/2014/301304
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
An overview of available therapies for acne and associated factors.
| Class | Drug | Dose | Mode of action | Clinical evidence | Adverse effects | Reference |
|---|---|---|---|---|---|---|
| Retinoids | Tretinoin | 0.01–0.05% | Anti comedogenic effect, indirect antimicrobiotic effect; anti-inflammatory, ability to regulate keratinocyte desquamation | Mild comedonal acne | Low grade irritant dermatitis with erythema and scaling, burning, photosensitivity | [ |
| Isotretinoin | 1.0–2.0 mg/kg/day | Inhibits sebaceous gland differentiation and proliferation, reduces sebaceous gland size, suppresses sebum production, normalizes follicular epithelial desquamation, regulates keratinocyte—keratinocyte adhesion, antiinflammatory effect | Severe recalcitrant | Cheilitis, conjunctivitis, hyper triglyceridemia, elevated serum cholesterol levels and liver enzymes, blood dyscrasias, dry eyes and mouth, photosensitivity, and pruritus; incidence/risk of teratogenicity, myalgia, arthralgia, headaches, malaise, mood swings and depression; acne fulminans, characterized by extensive erosive lesions, fever, arthralgias, leukocytosis premature epiphyseal closure in young children, asthma exacerbation, skin fragility, spectrum of ophthalmological disturbances, from dry eyes to optic neuritis | ||
| Adapalene | 0.1%–0.3% | Anti comedogenic effect, indirect antimicrobiotic effect | Mild to moderate | Irritation, contraindicated in pregnant women | ||
| Tazarotene | 0.05% or 0.1% | |||||
| Retinol | 0.04%–0.07% | Photosensitivity, xerosis, cheilitis | ||||
|
| ||||||
| Keratolytics | Azelaic acid | 20% | Anticomedogenic and antimicrobial effect, reduces the production of keratohyalin granules in the pilosebaceous duct and thus normalizes the ductal hypercornification; keratolytic and anti-inflammatory | Mild to moderate acne | Only a slight sensation of burning or tingling, mild erythema | [ |
| Benzoyl peroxide | 1%–10% | Antimicrobial effect (reactive oxygen species are generated that kill bacteria by oxidizing constituents of their cell membranes), antiinflammatory, very mild anti comedogenic effects, keratolytic | Inflammatory acne, | Irritant dermatitis with erythema and scaling, dryness, peeling, stinging, or burning, bleach hair, clothes, and bed linens | ||
| Salicylic acid | 2% | Anti-inflammatory, topical desquamating agent, comedolytic | Comedonal acne | Peeling, hyperpigmentation, toxic inner ear damage, hypoglycemia, hypersensitivity, acute salicylate intoxication | [ | |
| Sulfur | 1–10% | Keratolytic activity | Malodor and dry skin | |||
| Zinc | 200 mg/day (Zn gluconate), 400 or 600 mg/day (Zn sulfate ) | Bacteriostatic, inhibits chemotaxis, and may decrease tumor necrosis factor— | Mild or moderate acne, severe and inflammatory acne | Nausea, vomiting, and diarrhoea with gastrointestinal side effects | ||
| Alpha hydroxyl acids (Glycolic and lactic acid) | 10% | Exfoliative capabilities, promotes epidermolysis, disperse basal layer melanin, increases collagen synthesis within the dermis | ||||
| Sodium sulfacetamide | 10% with 5% sulphur | Inhibiting | Inflammatory lesions and | Mild transient dryness, itching | ||
|
| ||||||
| Antibiotics | Erythromycin | 2%–4% | Antimicrobial effect, a significant decrease of free fatty acids of the skin surface lipids, as a marker of | Moderate to severe | Bacterial resistance and cross resistance | [ |
| Clindamycin | 1% | Antibacterial, anti-inflammatory | Inflamed lesions | Antibiotic resistance, diarrhoea, pseudomembranous colitis | ||
| Tetracycline | 500 to 1000 mg/day | Suppress leukocyte chemotaxis and bacterial lipase activity | Moderate to severe inflammatory acne | Drug-induced lupus erythematous or a dose-duration pigmentation, abdominal colic, diarrhoea and vaginal candidiasis, enamel hypoplasia and a yellowish discoloration of the forming teeth, gastrointestinal discomfort, less commonly, photosensitivity, esophagitis, pancreatitis and pseudo-porphyria | ||
| Minocycline | 75–200 mg/day | Inhibits cytokines and matrix metalloproteinases thought to contribute to inflammation and tissue breakdown | Mild papulopustular acne | Urticaria to drug induced lupus, vertigo, dizziness, ataxia, and rarely a bluish discoloration of the skin, autoimmune hepatitis, hyper sensitivity syndrome | ||
| Doxycycline | 50 to 100 mg twice Daily | Photosensitivity reactions, gastrointestinal disturbances | ||||
| Trimethoprim/ | Anti-inflammatory effect, antibacterial, blocks dihydrofolate reductase/dihydropteroate synthetase, which ultimately diminishes bacterial purine and pyrimidine synthesis | Thrombocytopenia, agranulocytosis anemia, hypersensitivity | ||||
|
| ||||||
| Hormonal therapy | Spironolactone | 50–100 mg/day | Androgen receptor blocker, which decreases androgen-stimulated sebocyte proliferation, inhibit androgen biosynthesis by decreasing type II 17 | Moderate acne in women | Hyperkalemia, diuretic effect, dysmenorrhea, dysphoria, breast tenderness menstrual irregularities, lethargy, headache, lightheadedness, dizziness, orthostatic hypotension, gynaecomastia in men | [ |
| Flutamide | 250–500 mg/day | Converted to its highly potent metabolite, 2-hydroflutamide, which acts to selectively inhibit the binding of dihydrotestosterone to the androgen receptor | Hepatotoxicity and GIT disturbances, hot flashes, and decreased libido | |||
| Cyproterone acetate | 50–100 mg/day | Reduce sebum production, comedogenesis | Hepatotoxicity, breast tenderness, headache, nausea, breakthrough bleeding | |||
| Ethinyl estradiol | 20–35 | Reduce the production of androgens and sebum by inhibiting LH and FSH, thereby suppressing ovulation and ovarian androgen production, increasing sex hormone binding globulin and by decreasing levels of freely circulating testosterone and inhibit ovarian androgen production | Nausea, mood changes, contraindications to using OCs in an otherwise healthy woman include smoking, migraine headaches with aura and hypertension | |||
| Norgestimate, Norethindrone, Drospirenone | 35 | Suppress ovarian androgens and reduce bioavailable testosterone by an estrogen-mediated increase in steroid hormone binding globulin | ||||
| prednisone | 2.5 to 5 mg/d | Adrenal androgen-production blockers | ||||
Novel drug delivery systems for antiacne agent.
| Novel drug delivery carrier | Drug entrapped | Method of preparation | Problem statement | Advantages | Reference |
|---|---|---|---|---|---|
| Nanoparticles | Chitosan Alginate | Ultrasonication | Low solubility | Enhanced antimicrobial activity | [ |
| Minocycline | Ion pairing | Lack of drug loading and entrapment efficiency due to hydrophilicity of the drug | Enhanced drug loading and entrapment efficiency and controlled release | [ | |
| Azelaic acid | Emulsification solvent diffusion | Fewer side effects | Enhanced drug retention at PSU and stability | [ | |
| Triclosan | Solvent displacement | Insufficient permeation and absorption via cutaneous route | Non-irritant to skin, enhanced stability | [ | |
| Cyproterone acetate | Ultrasonication | Systemic antiandrogenic effects | Increased skin penetration and absorption | [ | |
|
| Solvent Displacement; | Water insolubility | Increased follicular penetration and absorption; Increased therapeutic activity | [ | |
|
| |||||
| Niosomes | Gallidermin | Freeze drying | For oral administration only and systemic pass demerits | Topical formulation with enhanced chemical stability | [ |
| Tretinoin | Thin film hydration | Photodegradation | Increased accumulation in superficial stratum and stability, Increased drug release and entrapment efficiencies | [ | |
| Rosmarinic acid | Reverse phase evaporation | Low water solubility | Increased skin retention of drug and facilitated prolong release | [ | |
|
| |||||
| Liposomes | Isotretinoin | Sonication | Skin irritation, very low water solubility, difficulty to incorporate in topical base, photodegradation | Potential for skin targeting, prolonging drug release, reduction of photodegradation and skin irritation | [ |
| Clindamycin hydrochloride | Film formation | Lesser reduction in number of lesions | Enhanced antiacne activity and sustained release of drug | [ | |
| Finasteride | Film formation | Only oral administration possible | Topical application with enhanced drug concentration | [ | |
| Tretinoin | Film formation | Skin irritant, photo instability | Enhanced local tolerability and 5-6 times increase comedolytic activity, | [ | |
| Tea tree oil | Ultrasonication | Lesser absorption via follicular route | Facilitated follicular route absorption | [ | |
| Salicylic acid | Thin film hydration | Skin irritant | Increased entrapment efficiency and stability | [ | |
| Cyproterone acetate | — | Systemic antiandrogenic effects | Increased activity by reducing acne lesions and adverse effects | [ | |
| Benzoyl peroxide | Film hydration | Skin irritation | Improved antibacterial activity, reduced irritation | [ | |
|
| |||||
| Solid lipid nanoparticles | Isotretinoin | Microemulsification | Teratogenicity, mucocutaneous problems like cheilitis, dermatitis, conjunctivitis, blepharitis, skin fragility and xerosis, psychological disorders, erythema, dryness, itching, stinging, skin peeling | Reduced dermal irritation, increased therapeutic performance | [ |
| Retinoic acid | Hot melt homogenization | Sensitive to sunlight, eczematous irritation, erythema, interaction with other applied products | Comedolytic effect, reduction in RA induced irritation | [ | |
| Neem oil | Double emulsification | Lesser drug absorption | Prolonged treatment of acne | [ | |
| Tretinoin | Hot high pressure homogenization | Skin irritation and chemical instability | High encapsulation efficacy, physical stability and absence of cytotoxicity | [ | |
| Terbinafine hydrochloride | Solvent Injection | Longer duration of treatment | Controlled release, drug targeting | [ | |
|
| |||||
| Nanosuspension | Tretinoin | Precipitation | Poor water solubility and photostability | Improved drug permeation and UV irradiation stability | [ |
|
| |||||
| Nanoemulsion | Tretinoin, Tetracycline | Sonication | Skin irritation, a burning sensation, and peeling | Enhanced drug permeation and antibacterial activity | [ |
|
| |||||
| Nano lipid carriers | Tretinoin, Tetracycline | Sonication | Skin irritation, a burning sensation, and peeling | Enhanced drug permeation and antibacterial activity | [ |
|
| |||||
| Microemulsions | Azelaic acid | — | Large and frequent dosing | Enhanced stability | [ |
| Niflumic acid | Homogenization | Weak solubility in oil and aqueous phases | Increased bioavailability at lesser concentration | [ | |
| Retinoic acid | Homogenization | Systemic side effects | Enhanced skin accumulation of retinoic acid | [ | |
|
| |||||
| Microspheres | Benzoyl peroxide | Emulsification | Skin irritation | Appropriate reduction in | [ |
| Retinoid | Emulsification | Skin irritation and instability | Reduced irritation and enhanced stability | [ | |
|
| |||||
| Hydrogel Patches | Triclosan | Film gelation | Insufficient permeation and absorption via cutaneous route | Enhanced transdermal penetration | [ |